[go: up one dir, main page]

US20130136733A1 - Stable Multi-Dose Compositions Comprising an Antibody and a Preservative - Google Patents

Stable Multi-Dose Compositions Comprising an Antibody and a Preservative Download PDF

Info

Publication number
US20130136733A1
US20130136733A1 US13/699,847 US201113699847A US2013136733A1 US 20130136733 A1 US20130136733 A1 US 20130136733A1 US 201113699847 A US201113699847 A US 201113699847A US 2013136733 A1 US2013136733 A1 US 2013136733A1
Authority
US
United States
Prior art keywords
composition
composition according
cresol
phenol
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/699,847
Other languages
English (en)
Inventor
Henrik Parshad
Dorthe Kot Engelund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to US13/699,847 priority Critical patent/US20130136733A1/en
Assigned to NOVO NORDISK A/S reassignment NOVO NORDISK A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ENGELUND, DORTE KOT, PARSHAD, HENRIK
Publication of US20130136733A1 publication Critical patent/US20130136733A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Definitions

  • the invention relates to stable, multi-dose liquid compositions containing proteins, in particular, but not exclusively stable antibodies, and to the use of said compositions in therapy, in particular for the subcutaneous delivery of said stable protein.
  • Immunoglobulins, monoclonal antibodies (mAbs) and humanized antibodies have been in development as pharmaceutical products for a number of years.
  • multi-dose formulations of mAbs must contain antimicrobial agents to protect them from microbial contamination during multiple dosage withdrawal.
  • Multi-dose formulations containing preservatives offer several advantages over single dose containers. For example, product wastage is minimized because different sized doses may be obtained from the same container. Additionally, doses may be obtained from the same container over a period of time without the concern for microbial growth.
  • packaging is minimized because multiple doses are supplied in a single vial.
  • Aggregate formation by a polypeptide during storage of a liquid pharmaceutical composition can adversely affect biological activity of that polypeptide, resulting in loss of therapeutic efficacy of the pharmaceutical composition. Furthermore, aggregate formation may cause other problems such as blockage of tubing, membranes, or pumps when the polypeptide-containing pharmaceutical composition is administered using an infusion system.
  • US 2004/0009168 (Kaisheva et al) describes a multidose IgG formulation comprising a preservative.
  • WO 2008/071394 (F. Hoffmann-La Roche) describes a stable pharmaceutical parenteral formulation containing an amyloid-beta peptide antibody.
  • US 2007/0053871 (Li et al) describes a stable pharmaceutical formulation comprising a protein or antibody, a destabilizing concentration of preservative and a stabilizing concentration of osmolyte.
  • WO 00/15224 (Eli Lilly and Company) describes a stable, soluble formulation comprising a protein, hydrophobic preservative and nicotinamide.
  • WO 2008/121615 (MedImmune, Inc) describes a high concentration liquid formulation of an antibody.
  • WO 2009/070642 MedImmune, Inc describes stable lyophilised formulations of bispecific antibodies.
  • US 2004/0197324 (Genentech, Inc) describes high concentration antibody and protein formulations with reduced viscosity, that are stable, relatively isotonic and are of low turbidity.
  • US 2008/0112953 (Amgen, Inc) describes a stable formulation comprising an EGFR antibody and a glutamic acid buffer.
  • U.S. Pat. No. 6,875,432 (Genentech, Inc) describes a concentrated protein formulation with reduced viscosity.
  • a stable, multi-dose liquid composition comprising an antibody and one or more preservatives.
  • a stable, multi-dose liquid composition as defined herein for use in therapy is provided.
  • a stable, multi-dose liquid composition comprising an antibody and one or more preservatives.
  • Benzyl alcohol has been demonstrated to bind to and accelerate aggregation of partially unfolded proteins.
  • a concentration of 1% benzyl alcohol resulted in cloudiness and the formation of soluble aggregates.
  • Concentrations of benzyl alcohol greater than 2% in the same monoclonal antibody formulation resulted in precipitation of the protein.
  • stable composition refers to a composition with satisfactory physical stability, satisfactory chemical stability or satisfactory physical and chemical stability.
  • the term “physical stability” of the protein composition as used herein refers to the tendency of the protein to form biologically inactive and/or insoluble aggregates of the protein as a result of exposure of the protein to thermo-mechanical stresses and/or interaction with interfaces and surfaces that are destabilizing, such as hydrophobic surfaces and interfaces.
  • Physical stability of the aqueous protein compositions is evaluated by means of visual inspection and/or turbidity measurements after exposing the composition filled in suitable containers (e.g. cartridges or vials) It is an inherent quality of highly concentrated formulations of mabs to exhibit opalescence due to Raleigh scattering. Thus, a composition cannot be classified as physically unstable with respect to protein aggregation, when it shows visual turbidity in daylight. However, when there are precipitates or phase separation visible in day light the formulation is classified as physically unstable.
  • chemical stability of the protein composition refers to chemical covalent changes in the protein structure leading to formation of chemical degradation products with potential less biological potency and/or potential increased immunogenic properties compared to the native protein structure.
  • chemical degradation products can be formed depending on the type and nature of the native protein and the environment to which the protein is exposed. Elimination of chemical degradation can most probably not be completely avoided and increasing amounts of chemical degradation products is often seen during storage and use of the protein composition is well-known by the person skilled in the art.
  • Most proteins are prone to deamidation, a process in which the side chain amide group in glutaminyl or asparaginyl residues is hydrolysed to form a free carboxylic acid.
  • Oxidation (of for instance methionine residues) can be mentioned as another variant of chemical degradation.
  • the chemical stability of the protein composition can be evaluated by measuring the amount of the chemical degradation products at various time-points after exposure to different environmental conditions (the formation of degradation products can often be accelerated by for instance increasing temperature).
  • the amount of each individual degradation product is often determined by separation of the degradation products depending on molecule size and/or charge using various chromatography techniques (e.g. SEC-HPLC and/or RP-HPLC).
  • SEC-HPLC is in particular used for quantification of protein aggregates.
  • the samples may for instance be analysed using a TSK G3000 SWXL column, isocratic elution and subsequent UV detection at 214 nm.
  • This method is used to determine monomeric IgG content and % High Molecular Weight Proteins (HMWP) consisting of dimeric species or larger which are separated according to size by the gel resin.
  • the monomeric content and % HMWP are determined relative to the total protein content detected by the method.
  • a stable composition refers to a composition with satisfactory physical stability, satisfactory chemical stability or satisfactory physical and chemical stability.
  • a satisfactory stability of a formulation may be measured by the increase of % High Molecular Weight Proteins ( ⁇ % HMWP).
  • ⁇ % HMWP % High Molecular Weight Proteins
  • a satisfactory stability of a formulation may be one wherein the increase is less than 10% and preferably less than 5% of the protein found as an aggregate ( ⁇ % HMWP) in the formulation over the testing period.
  • a composition must be stable during use and storage (in compliance with recommended use and storage conditions) until the expiration date is reached.
  • protein means a compound composed of at least five constituent amino acids connected by peptide bonds.
  • the constituent amino acids may be from the group of the amino acids encoded by the genetic code and they may be natural amino acids which are not encoded by the genetic code, as well as synthetic amino acids.
  • Natural amino acids which are not encoded by the genetic code are e.g. hydroxyproline, y-carboxyglutamate, ornithine, phosphoserine, D-alanine and D-glutamine.
  • Synthetic amino acids comprise amino acids manufactured by chemical synthesis, i.e.
  • D-isomers of the amino acids encoded by the genetic code such as D-alanine and D-leucine, Aib (a-aminoisobutyric acid), Abu ( ⁇ -aminobutyric acid), Tle (tert-butylglycine), ⁇ -alanine, 3-aminomethyl benzoic acid and anthranilic acid.
  • preservative refers to pharmaceutically acceptable excipients which prevent the growth of micro-organisms within the composition. More particularly, the invention provides a preservative containing multi-dose liquid composition which protects the composition against microbial contamination.
  • the preservative is present within the composition in an amount of between 0.001 to 2% (w/v). In one embodiment, the preservative is present within the composition in an amount of between 0.002 to 1% (w/v).
  • the one or more preservative is selected from phenol, m-cresol, benzyl alcohol, chlorobutanol, ethanol, phenoxyethanol, p-chlor-m-cresol, methyl paraben, propyl paraben, benzalkonium chloride, thiomersal or any combinations thereof.
  • the one or more preservative is selected from phenol, m-cresol, benzyl alcohol and chlorobutanol.
  • the composition comprises a single preservative. In one embodiment, the composition comprises a single preservative selected from phenol, m-cresol, benzyl alcohol, chlorobutanol, ethanol, phenoxyethanol, p-chlor-m-cresol, methyl paraben, propyl paraben, benzalkonium chloride and thiomersal.
  • phenol is typically present within the composition in an amount from 0.1 to 1% (w/v), such as 0.1 to 0.5% (w/v), such as 0.15 or 0.5% (w/v), in particular, 0.25 to 0.5% (w/v).
  • m-cresol is typically present within the composition in an amount from 0.1 to 1% (w/v), such as 0.1 to 0.5% (w/v), such as 0.15 or 0.35% (w/v), in particular, approximately 0.3% (w/v).
  • benzyl alcohol is typically present within the composition in an amount from 0.1 to 2% (w/v), such as 0.1 to 1.5% (w/v), such as 0.5 or 1.1% (w/v), in particular, approximately 1% (w/v).
  • chlorobutanol is typically present within the composition in an amount from 0.1 to 1% (w/v), such as 0.25 to 0.75% (w/v), such as 0.3 or 0.6% (w/v), in particular, approximately 0.3 to 0.5% (w/v).
  • methyl paraben is typically present within the composition in an amount from 0.1 to 0.5% (w/v), such as approximately 0.2% (w/v).
  • propyl paraben is typically present within the composition in an amount from 0.1 to 0.5% (w/v), such as approximately 0.2% (w/v).
  • phenoxyethanol is typically present within the composition in an amount from 0.1 to 2% (w/v), such as approximately 1% (w/v).
  • composition comprises thiomersal as a single preservative
  • thiomersal is typically present within the composition in an amount from 0.002 to 0.01% (w/v).
  • the composition comprises a single preservative selected from phenol, m-cresol, benzyl alcohol and chlorobutanol.
  • the composition comprises two or more preservatives. In one embodiment, the composition comprises two preservatives. Data is presented herein which surprisingly demonstrates that a lower amount of aggregates were observed for compositions comprising two preservatives when compared with the aggregation observed for the individual preservatives. In a yet further embodiment, the composition comprises two preservatives selected from phenol, m-cresol, benzyl alcohol, chlorobutanol, ethanol, phenoxyethanol, p-chlor-m-cresol, methyl paraben, propyl paraben, benzalkonium chloride and thiomersal.
  • the composition comprises two preservatives selected from phenol, m-cresol, benzyl alcohol and chlorobutanol.
  • preservatives selected from phenol, m-cresol, benzyl alcohol and chlorobutanol.
  • examples of such compositions comprising two preservatives include: phenol and m-cresol; and benzyl alcohol and chlorobutanol.
  • the concentration of each individual preservative will typically be lower than when a single preservative is used.
  • the composition comprises phenol and m-cresol as a two preservative containing composition
  • phenol is typically present within the composition in an amount from 0.1 to 0.75% (w/v), such as 0.1 to 0.5% (w/v), e.g. 0.15 or 0.5% (w/v)
  • m-cresol is typically present within the composition in an amount from 0.1 to 0.5% (w/v), such as 0.15 to 0.4% (w/v), e.g. 0.18 or 0.35% (w/v).
  • composition comprises benzyl alcohol and chlorobutanol as a two preservative containing composition
  • benzyl alcohol is typically present within the composition in an amount from 0.25 to 1% (w/v), such as 0.4 to 0.9% (w/v), e.g. 0.5 or 0.8% (w/v)
  • chlorobutanol is typically present within the composition in an amount from 0.1 to 0.5% (w/v), such as 0.1 to 0.4% (w/v), e.g. 0.11 or 0.3% (w/v).
  • the composition additionally comprises a salt.
  • the salt can have a buffering capacity at the relevant pH.
  • the salt is an inorganic salt, or an organic salt or a combination of one or more of these.
  • the salt is selected from the group consisting of sodium chloride, magnesium chloride, sodium thiocyanate, ammonium thiocyanate, ammonium sulfate, ammonium chloride, calcium chloride, arginine hydrochloride, zinc chloride, sodium acetate, amino acids or a combination thereof.
  • the salt is sodium chloride or magnesium chloride, optionally in combination with other salts.
  • the salt is arginine hydrochloride.
  • the salt is a combination of an inorganic salt and arginine hydrochloride.
  • the salt is an amino acid. In one embodiment the L-stereoisomer of the amino acid is used. In one embodiment, the salt is selected from arginine, glycine, lysine, aspartic acid, or glutamic acid, or a combination thereof. In one embodiment, the amino acid is arginine or glycine. In one embodiment, the amino acid is arginine, such as L-arginine. The amino acid can be added to the composition in its salt form or in its free form, whatever is suitable.
  • the composition additionally comprises a buffer.
  • the buffer is a suitable pharmaceutically acceptable buffer, which comprises both a pharmaceutically acceptable base and a pharmaceutically acceptable acid.
  • the buffer has a pKa of between 4 and 8, such as 5 to 7.
  • the buffer may be a salt.
  • Examples of pharmaceutically acceptable acid and bases may include inorganic as well as organic non-toxic acid/bases such as is well-known in the art. Examples are dosodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, maleate, succinate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and tris(hydroxymethyl)-amino methane, or mixtures thereof. Each one of these specific buffers constitutes an alternative embodiment of the invention.
  • the pharmaceutically acceptable buffer comprises histidine, maleate, succinate, phosphate, or tris(hydroxymethyl)-amino methane.
  • the pharmaceutically acceptable buffer comprises histidine.
  • the buffer has a pKa value ⁇ 1 pH unit from the target pH of the composition.
  • the composition is buffered to a pH of between 5 and 7, such as a pH of 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9 or 7.0, or to a pH as defined by any ranges there between.
  • the composition is buffered to a pH of between 6.0 and 7.0, such as 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9 or 7.0, or to a pH as defined by any ranges there between.
  • the composition is buffered to a pH of between 6.0 and 6.5.
  • the composition is buffered to a pH of 6.0 or 6.5, such as 6.5.
  • the composition additionally comprises a surfactant.
  • the surfactant is selected from a detergent, ethoxylated castor oil, polyglycolyzed glycerides, acetylated monoglycerides, sorbitan fatty acid esters, polyoxypropylene-polyoxyethylene block polymers (eg. poloxamers such as Pluronic® F68, poloxamer 188 and 407, Triton X-100), polyoxyethylene sorbitan fatty acid esters, polyoxyethylene and polyethylene derivatives such as alkylated and alkoxylated derivatives (Polysorbates, e.g.
  • Tween-20, Tween-40, Tween-80 and Brij-35 monoglycerides or ethoxylated derivatives thereof, diglycerides or polyoxyethylene derivatives thereof, alcohols, glycerol, lectins and phospholipids (eg. phosphatidyl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, diphosphatidyl glycerol and sphingomyelin), derivates of phospholipids (eg. dipalmitoyl phosphatidic acid) and lysophospholipids (eg.
  • phospholipids eg. dipalmitoyl phosphatidic acid
  • lysophospholipids eg.
  • ceramides e.g. sodium tauro-dihydrofusidate etc.
  • C6-C12 e.g.
  • acylcarnitines and derivatives N ⁇ -acylated derivatives of lysine, arginine or histidine, or side-chain acylated derivatives of lysine or arginine, N ⁇ -acylated derivatives of dipeptides comprising any combination of lysine, arginine or histidine and a neutral or acidic amino acid, N ⁇ -acylated derivative of a tripeptide comprising any combination of a neutral amino acid and two charged amino acids, DSS (docusate sodium, CAS registry no [577-11-7]), docusate calcium, CAS registry no [128-49-4]), docusate potassium, CAS registry no [7491-09-0]), SDS (sodium dodecyl sulphate or sodium lauryl sulphate), sodium caprylate, cholic acid or derivatives thereof, bile acids and salts thereof and glycine or taurine conjugates
  • DSS docusate sodium, CAS
  • N-alkyl-N,N-dimethylammonio-1-propanesulfonates 3-cholamido-1-propyldimethylammonio-1-propanesulfonate
  • cationic surfactants quaternary ammonium bases
  • cetyl-trimethylammonium bromide cetylpyridinium chloride
  • non-ionic surfactants eg. Dodecyl ⁇ -D-glucopyranoside
  • poloxamines eg.
  • Tetronic's which are tetrafunctional block copolymers derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine, or the surfactant may be selected from the group of imidazoline derivatives, or mixtures thereof. Each one of these specific surfactants constitutes an alternative embodiment of the invention.
  • the surfactant is Tween 80 (i.e. polysorbate 80).
  • the surfactant is present within the composition in an amount of below 0.01%. In one embodiment, the surfactant is present within the composition in an amount of below 0.0075%, i.e between 0.001% and 0.005%, such as 0.001%. In one embodiment, no surfactant is present.
  • the composition additionally comprises a tonicity modifying agent.
  • suitable tonicity modifying agents include salts (e.g sodium chloride), polyhydric alcohols (e.g propyleneglycol, glycerol, xyllitol. mannitol or D-sorbitol), monosaccarides (glucose or maltose), di saccarides (e.g sucrose), amino acids (L-glycine, L-histidine, arginine, lysine, isoleucine, aspartic acid, tryptophane, threonine), polyethylen glycols (e.g PEG 400) or mixtures thereof.
  • salts e.g sodium chloride
  • polyhydric alcohols e.g propyleneglycol, glycerol, xyllitol. mannitol or D-sorbitol
  • monosaccarides glucose or maltose
  • di saccarides e.
  • the tonicity modifying agent is sucrose, mannitol or propylene glycol. In one embodiment, the tonicity modifying agent is sucrose.
  • the buffer and/or salt of the composition also acts as a tonicity modifier or the tonicity modifier will act as a buffer and/or salt (and the concentration of the tonicity modifier will therefore in such cases be calculated as such).
  • the tonicity modifying agent is present within the composition in an amount of between 50 and 250 mM, such as between 100 and 200 mM, for example any one of 100, 110, 120, 130, 140, 150, 160, 170, 180, 190 or 200 or any ranges there between. In one embodiment, the tonicity modifying agent is present within the composition in an amount of 150 mM.
  • the composition is isotonic.
  • a stable, multi-dose liquid composition comprising a protein and one or more preservatives.
  • the protein is an immunoglobulin. In one embodiment, the protein is an antibody. In one embodiment, the protein is a monoclonal antibody (mAb). In one embodiment, the protein is an IgG4 antibody.
  • antibody covers monoclonal antibodies (including full length antibodies which have an immunoglobulin Fc region), antibody compositions with polyepitopic specificity, bispecific antibodies, diabodies, and single-chain molecules, as well as antibody fragments (e.g., Fab, F(ab′) 2 , and Fv).
  • the term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins.
  • the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
  • Suitable antibodies which may be formulated in a stable composition of the invention include: 3F8, Abagovomab, Abciximab, ACZ885 (canakinumab), Adalimumab, Adecatumumab, Afelimomab, Afutuzumab, Alacizumab pegol, Alemtuzumab, Altumomab pentetate, Anatumomab mafenatox, Anrukinzumab (IMA-638), Apolizumab, Arcitumomab, Aselizumab, Atlizumab (tocilizumab), Atorolimumab, Bapineuzumab, Basiliximab, Bavituximab, Bectumomab, Belimumab, Bertilimumab, Besilesomab, Bevacizumab, Biciromab, Bivatuzumab mertansine, Blinatum
  • the antibody is selected from an Anti-IL-20, Anti-TFPI, Anti-IL-21, Anti-C5Ar, Anti-NKGDA or Anti-NKG2a antibody.
  • the antibody is a monoclonal Anti-IL-20 antibody. In one embodiment, the antibody is an Anti-IL-20 antibody as described in WO 2010/000721. In one embodiment, the Anti-IL-20 monoclonal antibody is 15D2 or 5B7 as described in WO 2010/000721.
  • the antibody is a monoclonal Anti-TFPI antibody. In one embodiment, the antibody is an Anti-TFPI antibody as described in PCT/EP2009/067598. In one embodiment, the Anti-TFPI monoclonal antibody is HzTFPI4F36 as described in PCT/EP2009/067598.
  • the protein is present within the composition in high concentrations.
  • the protein is present in a concentration of 50 mg/ml or more, such as 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300 mg/ml or more.
  • the protein is present within the composition in an amount of between 50 mg/ml and 300 mg/ml, for instance between 50 mg/ml and 250 mg/ml, such as between 50 mg/ml and 200 mg/ml, for instance between 50 mg/ml and 150 mg/ml.
  • the protein is present in a concentration of between 75 mg/ml and 300 mg/ml, for instance between 75 mg/ml and 250 mg/ml, such as between 75 mg/ml and 200 mg/ml, for instance between 75 mg/ml and 150 mg/ml. In one embodiment, the protein is present in a concentration of between 100 mg/ml and 300 mg/ml, for instance between 100 mg/ml and 250 mg/ml, such as between 100 mg/ml and 200 mg/ml, for instance between 100 mg/ml and 150 mg/ml.
  • a protein composition of the invention comprises:
  • a protein composition of the invention comprises:
  • a protein composition of the invention comprises:
  • a protein composition of the invention comprises:
  • a protein composition of the invention comprises:
  • compositions of the invention have surprisingly demonstrated stability towards formation of high molecular weight proteins (HMWP) at 40° C. for 4 weeks and at 5° C. and 40° C. for 3 months.
  • HMWP high molecular weight proteins
  • a pharmaceutical formulation comprising the antibody and the excipients (including one or more preservatives) is prepared.
  • the pharmaceutical compositions of the invention are stable for more than 6 weeks of usage and for more than 3 years of storage.
  • the pharmaceutical compositions of the invention are stable for more than 4 weeks of usage and for more than 3 years of storage.
  • the pharmaceutical compositions of the invention are stable for more than 4 weeks of usage and for more than 2 years of storage.
  • the pharmaceutical compositions of the invention are stable for more than 2 weeks of usage and for more than 2 years of storage.
  • the pharmaceutical compositions of the invention are stable for more than 1 week of usage and for more than 6 months of storage.
  • a stable, multi-dose liquid composition as defined herein for use in therapy is provided.
  • treatment means the management and care of a patient for the purpose of combating a condition, such as a disease or a disorder.
  • the term is intended to include the full spectrum of treatments for a given condition from which the patient is suffering, such as administration of the active compound to alleviate the symptoms or complications, to delay the progression of the disease, disorder or condition, to alleviate or relieve the symptoms and complications, and/or to cure or eliminate the disease, disorder or condition as well as to prevent the condition, wherein prevention is to be understood as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of the active compounds to prevent the onset of the symptoms or complications.
  • the patient to be treated is preferably a mammal; in particular a human being, but it may also include animals, such as dogs, cats, cows, sheep and pigs.
  • the stable compositions of Anti-IL-20 antibodies of the present invention may be used in the treatment of an inflammatory disease, in particular autoinflammatory diseases, such as psoriasis, systemic lupus erythomatosus, rheumatoid arthritis, Crohn's disease and psoriatic arthritis or otherwise as described in WO 2010/000721.
  • autoinflammatory diseases such as psoriasis, systemic lupus erythomatosus, rheumatoid arthritis, Crohn's disease and psoriatic arthritis or otherwise as described in WO 2010/000721.
  • the invention provides a method of treating such an inflammatory disease which comprises administering to a patient a therapeutically effective amount of a stable composition of an Anti-IL-20 antibody of the present invention.
  • the invention also provides a stable composition of an Anti-IL-20 antibody of the present invention for use in the treatment of such an inflammatory disease.
  • the invention also provides the use of a stable composition of an Anti-IL-20 antibody of the present invention in the manufacture of a medicament for the treatment of such an inflammatory disease.
  • the invention also provides a stable pharmaceutical composition comprising a stable composition of an Anti-IL-20 antibody of the present invention for use in the treatment of such an inflammatory disease.
  • compositions of Anti-TFPI antibodies of the present invention may be used in the treatment of a coagulopathy (bleeding disorder), such as haemophilia A, with or without inhibitors, and haemophilia B, with or without inhibitors or otherwise as described in PCT/EP2009/067598.
  • a coagulopathy bleeding disorder
  • haemophilia A with or without inhibitors
  • haemophilia B with or without inhibitors or otherwise as described in PCT/EP2009/067598.
  • the invention provides a method of treating a coagulopathy which comprises administering to a patient a therapeutically effective amount of a stable composition of an Anti-TFPI antibody of the present invention.
  • the invention also provides a stable composition of an Anti-TFPI antibody of the present invention for use in the treatment of a coagulopathy.
  • the invention also provides the use of a stable composition of an Anti-TFPI antibody of the present invention in the manufacture of a medicament for the treatment of a coagulopathy.
  • the invention also provides a pharmaceutical composition comprising a stable composition of an Anti-TFPI antibody of the present invention for use in the treatment of a coagulopathy.
  • parenteral administration may be performed by subcutaneous, intramuscular, intraperitoneal or intravenous injection by means of a syringe, optionally a pen-like syringe.
  • parenteral administration can be performed by means of an infusion pump.
  • the formulations were prepared (see Table 1 below). The formulations were prepared from a stock solution containing ca. 150 mg/ml of the Anti-IL-20 antibody and 10 mM histidine buffer, pH 6.5. This stock solution was prepared by conventional UF/DF/UF. Stock solution of the excipients were prepared and mixed in the correct proportion. The final formulations were filled in 3 ml Penfill® cartridges, type 1 glass. The formulations were stored at 40° C. for 4 weeks and then analysed chemically, pharmaceutically and biophysically. The increase in the formation of protein aggregates (% HMWP) was measured by SEC-HPLC (as described above).
  • compositions containing 2 preservatives generally resulted in lower aggregate formation than the results achieved with the individual preservatives alone.
  • the composition containing 5 mg/ml phenol alone resulted in an increase of 2.5% HMWP
  • the composition containing 3.5 mg/ml m-cresol alone resulted in an increase of 3.1% HMWP
  • a composition containing a combination of these two preservatives at identical concentrations resulted in a lowering of aggregate formation (an increase of 1.2% HMWP).
  • An increase of 1.1% is seen for reference without preservative.
  • composition containing 3.5 mg/ml m-cresol resulted in the smallest increase in HMWP. After 3 months storage the increase in HMWP for this formulation is lower compared to reference without preservative.
  • composition containing phenol and m-cresol, respectively showed no increase in % HMWP over a period of 12 months at 5° C.
  • a preservative efficacy screening test was performed.
  • the efficacy of the preservative was measured using a modified USP/Ph Eur preservative efficacy test.
  • formulations were tested against Staphylococcus aureus . After inoculation, samples were stored for 6 and 24 hours at room temperature and the total bacterial counts were measured using a colony counter. The log reduction values were calculated as log (initial count/final count).
  • Embodiment 1 A stable, multi-dose liquid composition comprising an antibody and one or more preservatives.
  • Embodiment 2 A composition according to embodiment 1, wherein the preservative is present within the composition in an amount of between 0.001 to 2% (w/v).
  • Embodiment 3 A composition according to embodiment 1 or 2, wherein the preservative is present within the composition in an amount of between 0.002 to 1% (w/v).
  • Embodiment 4 A composition according to any of embodiments 1 to 3, wherein the one or more preservative is selected from phenol, m-cresol, benzyl alcohol, chlorobutanol, ethanol, phenoxyethanol, p-chlor-m-cresol, methyl paraben, propyl paraben, benzalkonium chloride, thiomersal or any combinations thereof.
  • the one or more preservative is selected from phenol, m-cresol, benzyl alcohol, chlorobutanol, ethanol, phenoxyethanol, p-chlor-m-cresol, methyl paraben, propyl paraben, benzalkonium chloride, thiomersal or any combinations thereof.
  • Embodiment 5 A composition according to any of embodiments 1 to 4, wherein the one or more preservative is selected from phenol, m-cresol, benzyl alcohol and chlorobutanol.
  • Embodiment 6 A composition according to any of embodiments 1 to 5, wherein the composition comprises a single preservative.
  • Embodiment 7 A composition according to any of embodiments 1 to 6, wherein the composition comprises a single preservative selected from phenol, m-cresol, benzyl alcohol, chlorobutanol, ethanol, phenoxyethanol, p-chlor-m-cresol, methyl paraben, propyl paraben, benzalkonium chloride and thiomersal.
  • a single preservative selected from phenol, m-cresol, benzyl alcohol, chlorobutanol, ethanol, phenoxyethanol, p-chlor-m-cresol, methyl paraben, propyl paraben, benzalkonium chloride and thiomersal.
  • Embodiment 8 A composition according to any of embodiments 1 to 7, which comprises phenol as a single preservative, wherein said phenol is present within the composition in an amount from 0.1 to 1% (w/v).
  • Embodiment 9 A composition according to any of embodiments 1 to 7, which comprises phenol as a single preservative, wherein said phenol is present within the composition in an amount from 0.1 to 0.5% (w/v).
  • Embodiment 10 A composition according to any of embodiments 1 to 7, which comprises phenol as a single preservative, wherein said phenol is present within the composition in an amount of 0.15 or 0.5% (w/v).
  • Embodiment 11 A composition according to any of embodiments 1 to 7, which comprises phenol as a single preservative, wherein said phenol is present within the composition in an amount from 0.25 to 0.5% (w/v).
  • Embodiment 12 A composition according to any of embodiments 1 to 7, which comprises m-cresol as a single preservative, wherein said m-cresol is present within the composition in an amount from 0.1 to 1% (w/v).
  • Embodiment 13 A composition according to any of embodiments 1 to 7, which comprises m-cresol as a single preservative, wherein said m-cresol is present within the composition in an amount from 0.1 to 0.5% (w/v).
  • Embodiment 14 A composition according to any of embodiments 1 to 7, which comprises m-cresol as a single preservative, wherein said m-cresol is present within the composition in an amount of 0.15 or 0.35% (w/v).
  • Embodiment 15 A composition according to any of embodiments 1 to 7, which comprises m-cresol as a single preservative, wherein said m-cresol is present within the composition in an amount of approximately 0.3% (w/v).
  • Embodiment 16 A composition according to any of embodiments 1 to 7, which comprises benzyl alcohol as a single preservative, wherein said benzyl alcohol is present within the composition in an amount from 0.1 to 2% (w/v).
  • Embodiment 17 A composition according to any of embodiments 1 to 7, which comprises benzyl alcohol as a single preservative, wherein said benzyl alcohol is present within the composition in an amount from 0.1 to 1.5% (w/v).
  • Embodiment 18 A composition according to any of embodiments 1 to 7, which comprises benzyl alcohol as a single preservative, wherein said benzyl alcohol is present within the composition in an amount of 0.5 or 1.1% (w/v).
  • Embodiment 19 A composition according to any of embodiments 1 to 7, which comprises benzyl alcohol as a single preservative, wherein said benzyl alcohol is present within the composition in an amount of approximately 1% (w/v).
  • Embodiment 20 A composition according to any of embodiments 1 to 7, which comprises chlorobutanol as a single preservative, wherein said chlorobutanol is present within the composition in an amount from 0.1 to 1% (w/v).
  • Embodiment 21 A composition according to any of embodiments 1 to 7, which comprises chlorobutanol as a single preservative, wherein said chlorobutanol is present within the composition in an amount from 0.25 to 0.75% (w/v).
  • Embodiment 22 A composition according to any of embodiments 1 to 7, which comprises chlorobutanol as a single preservative, wherein said chlorobutanol is present within the composition in an amount of 0.3 or 0.6% (w/v).
  • Embodiment 23 A composition according to any of embodiments 1 to 7, which comprises chlorobutanol as a single preservative, wherein said chlorobutanol is present within the composition in an amount from 0.3 to 0.5% (w/v).
  • Embodiment 24 A composition according to any of embodiments 1 to 7, which comprises methyl paraben as a single preservative, wherein said methyl paraben is present within the composition in an amount from 0.1 to 0.5% (w/v).
  • Embodiment 25 A composition according to any of embodiments 1 to 7, which comprises methyl paraben as a single preservative, wherein said methyl paraben is present within the composition in an amount of approximately 0.2% (w/v).
  • Embodiment 26 A composition according to any of embodiments 1 to 7, which comprises propyl paraben as a single preservative, wherein said propyl paraben is present within the composition in an amount from 0.1 to 0.5% (w/v).
  • Embodiment 27 A composition according to any of embodiments 1 to 7, which comprises propyl paraben as a single preservative, wherein said propyl paraben is present within the composition in an amount of approximately 0.2% (w/v).
  • Embodiment 28 A composition according to any of embodiments 1 to 7, which comprises phenoxyethanol as a single preservative, wherein said phenoxyethanol is present within the composition in an amount from 0.1 to 2% (w/v).
  • Embodiment 29 A composition according to any of embodiments 1 to 7, which comprises phenoxyethanol as a single preservative, wherein said phenoxyethanol is present within the composition in an amount of approximately 1% (w/v).
  • Embodiment 30 A composition according to any of embodiments 1 to 7, which comprises thiomersal as a single preservative, wherein said thiomersal is present within the composition in an amount from 0.002 to 0.01% (w/v).
  • Embodiment 31 A composition according to any of embodiments 1 to 7, which comprises a single preservative selected from phenol, m-cresol, benzyl alcohol and chlorobutanol.
  • Embodiment 32 A composition according to any of embodiments 1 to 5, which comprises two or more preservatives.
  • Embodiment 33 A composition according to embodiment 32, which comprises two preservatives.
  • Embodiment 34 A composition according to embodiment 32 or 33, which comprises two preservatives selected from phenol, m-cresol, benzyl alcohol, chlorobutanol, ethanol, phenoxyethanol, p-chlor-m-cresol, methyl paraben, propyl paraben, benzalkonium chloride and thiomersal.
  • Embodiment 35 A composition according to embodiment 34, which comprises two preservatives selected from phenol, m-cresol, benzyl alcohol and chlorobutanol.
  • Embodiment 36 A composition according to any of embodiments 32 to 35, wherein said two preservatives are phenol and m-cresol.
  • Embodiment 37 A composition according to embodiment 36, wherein phenol is present within the composition in an amount from 0.1 to 0.75% (w/v).
  • Embodiment 38 A composition according to embodiment 36 or 37, wherein phenol is present within the composition in an amount from 0.1 to 0.5% (w/v).
  • Embodiment 39 A composition according to any of embodiments 36 to 38, wherein phenol is present within the composition in an amount of 0.15 or 0.5% (w/v).
  • Embodiment 40 A composition according to any of embodiments 36 to 39, wherein m-cresol is present within the composition in an amount from 0.1 to 0.5% (w/v).
  • Embodiment 41 A composition according to any of embodiments 36 to 40, wherein m-cresol is present within the composition in an amount from 0.15 to 0.4% (w/v).
  • Embodiment 42 A composition according to any of embodiments 36 to 41, wherein m-cresol is present within the composition in an amount of 0.18 or 0.35% (w/v).
  • Embodiment 43 A composition according to any of embodiments 32 to 35, wherein said two preservatives are benzyl alcohol and chlorobutanol.
  • Embodiment 44 A composition according to embodiment 43, wherein benzyl alcohol is present within the composition in an amount from 0.25 to 1% (w/v).
  • Embodiment 45 A composition according to embodiment 43 or 44, wherein benzyl alcohol is present within the composition in an amount from 0.4 to 0.9% (w/v).
  • Embodiment 46 A composition according to any of embodiments 43 to 45, wherein benzyl alcohol is present within the composition in an amount of 0.5 or 0.8% (w/v).
  • Embodiment 47 A composition according to any of embodiments 43 to 46, wherein chlorobutanol is present within the composition in an amount from 0.1 to 0.5% (w/v).
  • Embodiment 48 A composition according to any of embodiments 43 to 47, wherein chlorobutanol is present within the composition in an amount from 0.1 to 0.4% (w/v).
  • Embodiment 49 A composition according to any of embodiments 43 to 48, wherein chlorobutanol is present within the composition in an amount of 0.11 or 0.3% (w/v).
  • Embodiment 50 A composition according to any embodiments 1 to 49, wherein a buffer is present, and the buffer has a pKa between 4 to 8.
  • Embodiment 51 A composition according to embodiment 50, wherein the buffer has a pKa between 5 to 7.
  • Embodiment 52 A composition according to embodiment 50 or 51, wherein a buffer is present, and the buffer is dosodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, maleate, succinate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, or tris(hydroxymethyl)-amino methane, or mixtures thereof.
  • a buffer is present, and the buffer is dosodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, maleate, succinate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, or tris(hydroxymethyl)-amino methane, or mixtures thereof.
  • Embodiment 53 A composition according to embodiment 52, wherein the buffer is histidine, maleate, succinate, phosphate, or tris(hydroxymethyl)-amino methane.
  • Embodiment 54 A composition according to embodiment 53, wherein the buffer is histidine.
  • Embodiment 55 A composition according to embodiment 54, wherein the buffer has a pKa value ⁇ 1 pH unit from the target pH of the composition.
  • Embodiment 56 A composition according to any of embodiments 1 to 55, wherein a salt is present and the salt is selected from the group consisting of sodium chloride, magnesium chloride, sodium thiocyanate, ammonium thiocyanate, ammonium sulfate, ammonium chloride, calcium chloride, arginine hydrochloride, zinc chloride and sodium acetate or any combination thereof.
  • Embodiment 57 A composition according to embodiment 56, wherein the salt is sodium chloride or magnesium chloride.
  • Embodiment 58 A composition according to embodiment 57, wherein the salt is sodium chloride.
  • Embodiment 59 A composition according to embodiment 56, wherein the salt is arginine-HCl.
  • Embodiment 60 A composition according to any of embodiments 1 to 59, which has a pH of between 5.0 and 7.0.
  • Embodiment 61 A composition according to embodiment 60, which has a pH of between 6.0 and 7.0.
  • Embodiment 62 A composition according to embodiment 61, which has a pH of 6.0 or 6.5.
  • Embodiment 63 A composition according to embodiment 62, which has a pH of 6.5.
  • Embodiment 64 A composition according to any of embodiments 1 to 63 which additionally comprises a surfactant.
  • Embodiment 65 A composition according to embodiment 64, wherein the surfactant is Tween 80 (i.e. polysorbate 80).
  • Embodiment 66 A composition according to embodiment 64 or 65, wherein the surfactant is present within the composition in an amount of below 0.01%.
  • Embodiment 67 A composition according to any of embodiments 64 to 66, wherein the surfactant is present within the composition in an amount of below 0.0075%.
  • Embodiment 68 A composition according to any of embodiments 64 to 67, wherein the surfactant is present within the composition in an amount between 0.001% and 0.005%.
  • Embodiment 69 A composition according to any of embodiments 64 to 68, wherein the surfactant is present within the composition in an amount of 0.001%.
  • Embodiment 70 A composition according to any of embodiments 1 to 63 wherein no surfactant is present.
  • Embodiment 71 A composition according to any of embodiments 1 to 70, which additionally comprises a tonicity modifying agent.
  • Embodiment 72 A composition according to embodiment 71, wherein the tonicity modifying agent is sucrose or propylene glycol.
  • Embodiment 73 A composition according to embodiment 72, wherein the tonicity modifying agent is sucrose.
  • Embodiment 74 A composition according to embodiment 72, wherein the tonicity modifying agent is propylene glycol.
  • Embodiment 75 A composition according to any of embodiments 71 to 74, wherein the tonicity modifying agent is present within the composition in an amount of between 50 and 250 mM.
  • Embodiment 76 A composition according to any of embodiments 71 to 75, wherein the tonicity modifying agent is present within the composition in an amount of between 100 and 200 mM.
  • Embodiment 77 A composition according to any of embodiments 71 to 76, wherein the tonicity modifying agent is present in an amount of 100 mM.
  • Embodiment 78 A composition according to any of embodiments 1 to 77, wherein the composition is pharmaceutically acceptable.
  • Embodiment 79 A stable composition according to any of embodiments 1 to 78,
  • the antibody is present within the composition in a concentration of between 50 mg/ml and 300 mg/ml.
  • Embodiment 80 A stable composition according to embodiment 79, wherein the antibody is present within the composition in a concentration of between 75 mg/ml and 300 mg/ml.
  • Embodiment 81 A stable composition according to embodiment 80, wherein the antibody is present within the composition in a concentration of between 100 mg/ml and 300 mg/ml.
  • Embodiment 82 A stable composition according to embodiment 81, wherein the antibody is present within the composition in a concentration of between 50 mg/ml and 200 mg/ml.
  • Embodiment 83 A stable composition according to embodiment 82, wherein the antibody is present within the composition in a concentration of 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, or 300 mg/ml.
  • Embodiment 84 A composition according to embodiment 1 which comprises:
  • Embodiment 85 A composition according to embodiment 1 which comprises:
  • Embodiment 86 A composition according to embodiment 1 which comprises:
  • Embodiment 87 A composition according to embodiment 1 which comprises:
  • Embodiment 88 A composition according to embodiment 1 which comprises:
  • Embodiment 89 A composition according to embodiment 1 which comprises:
  • Embodiment 90 A composition according to embodiment 1 which comprises:
  • Embodiment 91 A composition according to embodiment 1 which comprises:
  • Embodiment 92 A composition according to embodiment 1 which comprises:
  • Embodiment 93 A composition according to embodiment 1 which comprises:
  • Embodiment 94 A composition according to embodiment 1 which comprises:
  • Embodiment 95 A composition according any of embodiments 1-94, wherein the antibody is of the IgG4 subtype.
  • Embodiment 96 A composition according to any of embodiments 1 to 95, wherein the antibody is a monoclonal antibody.
  • Embodiment 97 A composition according to embodiment 96, wherein the monoclonal antibody is an Anti-IL-20 monoclonal antibody.
  • Embodiment 98 A composition according to embodiment 96, wherein the monoclonal antibody is an Anti-IL-20 monoclonal antibody as described in WO 2010/000721.
  • Embodiment 99 A composition according to embodiment 96, wherein the monoclonal antibody is an Anti-IL-20 antibody 15D2 or 5B7 as described in WO 2010/000721.
  • Embodiment 100 A composition according to embodiment 96, wherein the monoclonal antibody is an Anti-TFPI monoclonal antibody.
  • Embodiment 101 A composition according to embodiment 96, wherein the monoclonal antibody is the Anti-TFPI monoclonal antibody HzTFPI4F36 as described in PCT/EP2009/067598.
  • Embodiment 102 A stable, multi-dose liquid composition according to any of embodiments 1 to 101 for use in therapy.
  • Embodiment 103 A method of treating an inflammatory disease which comprises administering to a patient a therapeutically effective amount of a composition according to any of embodiments 97-99.
  • Embodiment 104 A composition according to any of embodiments 97-99 for use in the treatment of an inflammatory disease.
  • Embodiment 105 Use of a composition according to any of embodiments 97-99 in the manufacture of a medicament for the treatment of an inflammatory disease.
  • Embodiment 106 A pharmaceutical composition comprising an Anti-IL-20 composition according to any of embodiments 97-99 for use in the treatment of an inflammatory disease.
  • Embodiment 107 A method of treating a coagulopathy which comprises administering to a patient a therapeutically effective amount of a composition according to any of embodiments 100-101.
  • Embodiment 108 A composition according to any of embodiments 100-101 for use in the treatment of a coagulopathy.
  • Embodiment 109 Use of a composition according to any of embodiments 100-101 in the manufacture of a medicament for the treatment of a coagulopathy.
  • Embodiment 110 A pharmaceutical composition comprising an Anti-TFPI composition according to any of embodiments 100-101 for use in the treatment of a coagulopathy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
US13/699,847 2010-05-28 2011-05-26 Stable Multi-Dose Compositions Comprising an Antibody and a Preservative Abandoned US20130136733A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/699,847 US20130136733A1 (en) 2010-05-28 2011-05-26 Stable Multi-Dose Compositions Comprising an Antibody and a Preservative

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10164298 2010-05-28
EP10164298.1 2010-05-28
US35152210P 2010-06-04 2010-06-04
US13/699,847 US20130136733A1 (en) 2010-05-28 2011-05-26 Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
PCT/EP2011/058648 WO2011147921A1 (en) 2010-05-28 2011-05-26 Stable multi-dose compositions comprising an antibody and a preservative

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/058648 A-371-Of-International WO2011147921A1 (en) 2010-05-28 2011-05-26 Stable multi-dose compositions comprising an antibody and a preservative

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/799,276 Continuation US10835602B2 (en) 2010-05-28 2017-10-31 Stable multi-dose compositions comprising an antibody and a preservative

Publications (1)

Publication Number Publication Date
US20130136733A1 true US20130136733A1 (en) 2013-05-30

Family

ID=42562357

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/699,847 Abandoned US20130136733A1 (en) 2010-05-28 2011-05-26 Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
US15/799,276 Active 2031-06-16 US10835602B2 (en) 2010-05-28 2017-10-31 Stable multi-dose compositions comprising an antibody and a preservative

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/799,276 Active 2031-06-16 US10835602B2 (en) 2010-05-28 2017-10-31 Stable multi-dose compositions comprising an antibody and a preservative

Country Status (14)

Country Link
US (2) US20130136733A1 (ja)
EP (1) EP2575761B1 (ja)
JP (3) JP6294075B2 (ja)
KR (1) KR20130086144A (ja)
CN (2) CN102905692B (ja)
AU (1) AU2011257219B2 (ja)
BR (1) BR112012030139A2 (ja)
CA (1) CA2800188A1 (ja)
ES (1) ES2993022T3 (ja)
HR (1) HRP20241526T1 (ja)
MX (1) MX2012013586A (ja)
RS (1) RS66182B1 (ja)
RU (1) RU2012153786A (ja)
WO (1) WO2011147921A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9795674B2 (en) 2010-02-26 2017-10-24 Novo Nordisk A/S Stable antibody containing compositions
US9849181B2 (en) 2012-08-31 2017-12-26 Bayer Healthcare Llc High concentration antibody and protein formulations
USRE47150E1 (en) 2010-03-01 2018-12-04 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
US10835602B2 (en) 2010-05-28 2020-11-17 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
WO2021094917A1 (en) * 2019-11-13 2021-05-20 Pfizer Inc. Stable aqueous anti-tfpi antibody formulation

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102659945B (zh) 2002-01-25 2016-12-21 诺沃挪第克公司 抗C5aR抗体及其应用
MX2010009190A (es) 2008-02-20 2010-09-10 G2 Inflammation Pty Ltd Anticuerpos anti-c5ar humanizados.
KR20110039218A (ko) 2008-06-30 2011-04-15 노보 노르디스크 에이/에스 항－인간 인터루킨－２０ 항체
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
ES2929575T3 (es) 2011-06-06 2022-11-30 Novo Nordisk As Anticuerpos terapéuticos
NZ629204A (en) * 2012-02-16 2016-09-30 Santarus Inc Anti-vla1 (cd49a) antibody pharmaceutical compositions
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
PT2830658T (pt) * 2012-03-26 2018-12-28 Sanofi Sa Formulações de agente de ligação igg4 estável
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
KR102438650B1 (ko) 2015-08-19 2022-08-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
IL270239B2 (en) * 2017-05-05 2025-01-01 Amgen Inc Pharmaceutical composition containing bispecific antibody constructs for improved storage and delivery
SG11202101980VA (en) 2018-09-12 2021-03-30 Silverback Therapeutics Inc Methods and composition for the treatment of disease with immune stimulatory conjugates
KR102337683B1 (ko) 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
WO2020257407A1 (en) 2019-06-19 2020-12-24 Silverback Therapeutics, Inc. Anti-mesothelin antibodies and immunoconjugates thereof
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
CN116615454A (zh) 2020-08-12 2023-08-18 先天制药公司 采用艾朵利单抗的皮下抗c5ar拮抗剂治疗方案
JP7278503B2 (ja) * 2020-09-24 2023-05-19 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー コンシズマブの医薬製剤およびその生産方法
CN112244025A (zh) * 2020-11-27 2021-01-22 上海创宏生物科技有限公司 大分子蛋白和/或核酸用无菌处理剂及其制备方法和应用
CN120129534A (zh) * 2022-10-26 2025-06-10 日本医事物理股份有限公司 放射性药物组合物
TW202508625A (zh) * 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US20020099179A1 (en) 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JP3681206B2 (ja) 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
TW471180B (en) 1996-06-28 2002-01-01 Seiko Epson Corp Thin film transistor, its manufacturing method, circuit and liquid crystal display apparatus using thin film transistor
US5985614A (en) 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
PT963377E (pt) 1996-08-30 2009-05-11 Human Genome Sciences Inc Interleucina 19
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
JP2002505574A (ja) 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド ポリアルキレンオキシド修飾された単鎖ポリペプチド
US6486301B1 (en) 1997-07-16 2002-11-26 Human Genome Sciences, Inc. Interleukin-20
WO1999003982A1 (en) 1997-07-16 1999-01-28 Human Genome Sciences, Inc. Interleukin-20
CA2298439A1 (en) 1997-08-06 1999-02-18 Zymogenetics, Inc. Lipocalin homologs
US6576743B1 (en) 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
DE69918946T2 (de) 1998-01-23 2005-07-28 Immunex Corp., Seattle Rezeptoren für il-18
JP2002505879A (ja) 1998-03-09 2002-02-26 シェーリング コーポレイション ヒトレセプタータンパク質；関連する試薬および方法
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
WO1999061630A2 (en) 1998-05-26 1999-12-02 Regeneron Pharmaceuticals, Inc. Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
WO1999062934A1 (en) 1998-06-05 1999-12-09 Human Genome Sciences, Inc. Interferon receptor hkaef92
US7098312B2 (en) 1998-09-01 2006-08-29 Genetech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CN1317967A (zh) * 1998-09-17 2001-10-17 伊莱利利公司 蛋白质制剂
US6451286B1 (en) * 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
EP1141008A1 (en) 1998-12-31 2001-10-10 Millennium Pharmaceuticals, Inc. Class ii cytokine receptor-like proteins and nucleic acids encoding them
CA2383254A1 (en) 1999-06-02 2000-12-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20050060101A1 (en) 1999-06-28 2005-03-17 Bevilacqua Michael P. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
CN100389821C (zh) 1999-10-04 2008-05-28 希龙公司 稳定化的含多肽的液体药物组合物
KR100399156B1 (ko) * 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
DE60040240D1 (de) 1999-12-23 2008-10-23 Zymogenetics Inc Löslicher interleukin-20 rezeptor
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
CA2406128A1 (en) 2000-04-07 2001-10-18 Ellis L. Kline Methods and compositions for treating neoplasms
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
EP1336410A4 (en) 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd PROTEIN INJECTION PREPARATIONS
WO2002012345A2 (en) 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
EP1314437B1 (en) 2000-08-11 2014-06-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
CN1503677A (zh) 2001-02-28 2004-06-09 用lp82治疗造血障碍
ATE432942T1 (de) 2001-03-09 2009-06-15 Zymogenetics Inc Löslicher heterodimerer cytokinrezeptor
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
CA2460916A1 (en) 2001-10-04 2003-04-10 Laura Carter Methods and compositions for modulating interleukin-21 receptor activity
US7022289B1 (en) 2001-10-10 2006-04-04 The United States Of America As Represented By The Secretary Of The Army Chemical and biological sampling device and kit and method of use thereof
ES2624547T3 (es) * 2001-11-14 2017-07-14 Janssen Biotech, Inc. Anticuerpos anti il 6, composiciones, métodos y usos
IL161978A0 (en) 2001-12-17 2005-11-20 Zymogenetics Inc Method for treating cervical cancer
PL213311B1 (pl) 2002-02-14 2013-02-28 Chugai Pharmaceutical Co Ltd Preparat roztworu zawierajacego przeciwcialo
PT1946776T (pt) 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
CA2481304A1 (en) 2002-03-27 2003-10-09 Patrick Hwu Method for treating cancer in humans
US20040009168A1 (en) * 2002-04-05 2004-01-15 Elizabet Kaisheva Multidose antibody formulation
AU2005254062B2 (en) 2002-04-11 2011-02-17 Medimmune, Llc High pressure spray-dry of bioactive materials
EP2380633A1 (en) 2002-06-07 2011-10-26 ZymoGenetics, Inc. Use of IL-21 in cancer
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
EP1551875A4 (en) 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
AU2003281528A1 (en) 2002-07-18 2004-02-09 Fabio Perini S.P.A. Storage unit for elongated products
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
WO2004071439A2 (en) 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
PL1610820T5 (pl) * 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
GEP20104887B (en) 2003-07-15 2010-02-10 Medarex Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
HUE026793T2 (en) 2003-10-01 2016-07-28 Kyowa Hakko Kirin Co Ltd A method for stabilizing an antibody and a stabilized solution-type antibody preparation
US20070184050A1 (en) 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
BRPI0516975A (pt) 2004-10-22 2008-09-30 Zymogenetics Inc anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
JP2008532931A (ja) 2005-02-08 2008-08-21 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２０、抗ｉｌ−２２および抗ｉｌ−２２ｒａ抗体ならびに結合パートナー、ならびに炎症における使用法
US7525604B2 (en) 2005-03-15 2009-04-28 Naxellent, Llc Windows with electrically controllable transmission and reflection
WO2007003936A1 (en) 2005-07-02 2007-01-11 Arecor Limited Stable aqueous systems comprising proteins
WO2007006858A2 (en) 2005-07-12 2007-01-18 Oy Jurilab Ltd Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same
US7790679B2 (en) * 2005-08-05 2010-09-07 Amgen Inc. Pharmaceutical formulations
EP2161348A1 (en) 2005-09-27 2010-03-10 Source MDX Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
WO2007038501A2 (en) 2005-09-27 2007-04-05 The Feinstein Institute For Medical Research Rheumatoid arthritis markers
CN104984352A (zh) 2005-11-21 2015-10-21 圣诺菲·帕斯图尔有限公司 重组病毒的稳定制剂
CA2634131C (en) 2005-12-21 2014-02-11 Wyeth Protein formulations with reduced viscosity and uses thereof
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
DE102006005094A1 (de) 2006-02-04 2007-08-09 Degussa Gmbh Titandioxid und Polycarboxylatether enthaltende Dispersion
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
US20090128815A1 (en) 2006-03-15 2009-05-21 Koninklijke Philips Electronics N.V. Remote control pointing technology with roll detection
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
CA2644663A1 (en) 2006-03-23 2007-09-27 Kirin Pharma Kabushiki Kaisha Agonist antibody to human thrombopoietin receptor
AU2007229554A1 (en) * 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-IGF-1R human monoclonal antibody formulation
EP1857559A1 (en) 2006-05-16 2007-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting responsiveness to TNF alpha blocking agents
AU2007260769A1 (en) 2006-06-14 2007-12-21 Imclone Llc Lyophilized formulations of anti-EGFR antibodies
AU2007261019A1 (en) 2006-06-19 2007-12-27 Wyeth Methods of modulating IL-22 and IL-17
BRPI0712953B8 (pt) 2006-06-30 2021-05-25 Novo Nordisk As anticorpos anti-nkg2a, seu uso, e composição farmacêutica
MX2009003635A (es) 2006-10-06 2009-04-22 Amgen Inc Formulaciones de anticuerpos estables.
JP2010506839A (ja) 2006-10-12 2010-03-04 ワイス エルエルシー 乳光の低減を伴う方法および組成物
US20100267575A1 (en) 2006-10-17 2010-10-21 Childrens Hospital Medical Center Gene array technique for predicting response in inflammatory bowel diseases
CA2668955A1 (en) 2006-11-09 2008-05-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for predicting therapeutic responsiveness to tnf-alpha blocking agents
CA2671968A1 (en) 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
WO2009077483A1 (en) 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
AR064826A1 (es) 2007-01-09 2009-04-29 Wyeth Corp Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa
US20100273671A1 (en) 2007-03-01 2010-10-28 Universite Catholique De Louvain Method for the determination and the classification of rheumatic conditions
KR101087344B1 (ko) 2007-03-23 2011-11-25 파나소닉 주식회사 도전성 범프와 그 제조 방법 및 전자 부품 실장 구조체
CA2682170A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Antibodies with decreased deamidation profiles
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
WO2008132176A2 (en) 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy
EP2167687B1 (en) 2007-06-08 2013-03-27 Biogen Idec MA Inc. Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
HUE041555T2 (hu) 2007-06-14 2019-05-28 Biogen Ma Inc Natalizumab antitest készítmények formulációk
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
US20090004189A1 (en) 2007-06-18 2009-01-01 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
WO2009002521A2 (en) 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
EP2173163A4 (en) 2007-07-06 2010-12-08 Glaxosmithkline Llc ANTIBODY FORMULATIONS
US20110143351A1 (en) 2007-07-20 2011-06-16 National Institute For Biopr0Essing Research And Training Limited Glyosylation markers for cancer and chronic inflammation
US20100261613A1 (en) 2007-07-26 2010-10-14 Michael Centola Methods for inflammatory disease management
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
MX2010009190A (es) 2008-02-20 2010-09-10 G2 Inflammation Pty Ltd Anticuerpos anti-c5ar humanizados.
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
US20110105725A1 (en) 2008-05-15 2011-05-05 Novo Nordisk A/S Antibody purification process
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
KR20110039218A (ko) 2008-06-30 2011-04-15 노보 노르디스크 에이/에스 항－인간 인터루킨－２０ 항체
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
JP2012501184A (ja) 2008-08-28 2012-01-19 ワイス・エルエルシー 自己免疫疾患におけるｉｌ−２２、ｉｌ−１７、およびｉｌ−１ファミリーのサイトカインの使用
JP5524967B2 (ja) 2008-09-19 2014-06-18 エフ．ホフマン−ラ ロシュ アーゲー 新規抗体処方物
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
PT2379600E (pt) * 2008-12-22 2014-04-29 Novo Nordisk As Anticorpos contra inibidor da via de fator tecidual
DK2414542T3 (da) 2009-03-30 2017-11-27 Tel Hashomer Medical Res Infrastructure & Services Ltd Fremgangsmåder til forudsigelse af klinisk forløb for og behandling af multipel sklerose
RU2539112C2 (ru) 2009-09-03 2015-01-10 Дженентек, Инк. Способы лечения, диагностики и мониторинга ревматоидного артрита
US8580528B2 (en) 2009-10-16 2013-11-12 Stichting Vu-Vumc Method for prognosticating the clinical response of a patient to B-lymphocyte inhibiting or depleting therapy
EP2488875A4 (en) 2009-10-16 2013-02-27 Mayo Foundation DETERMINATION RHEUMATOID ARTHRITIS
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
AU2011257219B2 (en) * 2010-05-28 2014-12-04 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
JP2013529089A (ja) 2010-06-07 2013-07-18 エフ．ホフマン−ラ ロシュ アーゲー インターロイキン−６受容体を阻害するモノクローナル抗体による薬剤治療に対する応答を予測するための遺伝子発現マーカー
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9795674B2 (en) 2010-02-26 2017-10-24 Novo Nordisk A/S Stable antibody containing compositions
US10709782B2 (en) 2010-02-26 2020-07-14 Novo Nordisk A/S Stable antibody containing compositions
USRE47150E1 (en) 2010-03-01 2018-12-04 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
US10835602B2 (en) 2010-05-28 2020-11-17 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
US9849181B2 (en) 2012-08-31 2017-12-26 Bayer Healthcare Llc High concentration antibody and protein formulations
WO2021094917A1 (en) * 2019-11-13 2021-05-20 Pfizer Inc. Stable aqueous anti-tfpi antibody formulation
KR20220100634A (ko) * 2019-11-13 2022-07-15 화이자 인코포레이티드 안정한 수성 항-tfpi 항체 제제
KR102896927B1 (ko) 2019-11-13 2025-12-08 화이자 인코포레이티드 안정한 수성 항-tfpi 항체 제제
IL292493B1 (en) * 2019-11-13 2026-01-01 Pfizer Stable aqueous anti-TFPI antibody formulation

Also Published As

Publication number Publication date
WO2011147921A1 (en) 2011-12-01
CA2800188A1 (en) 2011-12-01
RU2012153786A (ru) 2014-07-10
JP6568917B2 (ja) 2019-08-28
US10835602B2 (en) 2020-11-17
KR20130086144A (ko) 2013-07-31
EP2575761C0 (en) 2024-08-14
EP2575761B1 (en) 2024-08-14
JP6294075B2 (ja) 2018-03-14
JP2016084367A (ja) 2016-05-19
CN105055306A (zh) 2015-11-18
EP2575761A1 (en) 2013-04-10
MX2012013586A (es) 2013-01-24
JP2013527189A (ja) 2013-06-27
CN105055306B (zh) 2019-10-01
US20180104335A1 (en) 2018-04-19
JP2018030879A (ja) 2018-03-01
JP6239657B2 (ja) 2017-11-29
CN102905692A (zh) 2013-01-30
HRP20241526T1 (hr) 2025-01-03
RS66182B1 (sr) 2024-12-31
BR112012030139A2 (pt) 2017-06-13
ES2993022T3 (en) 2024-12-20
CN102905692B (zh) 2015-09-16
AU2011257219B2 (en) 2014-12-04
AU2011257219A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
US10835602B2 (en) Stable multi-dose compositions comprising an antibody and a preservative
US10709782B2 (en) Stable antibody containing compositions
US20250367115A1 (en) Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions
US20170056504A1 (en) Method of extending half-life of crystaline antibodies
WO2016103034A1 (en) Protein compositions and use thereof
US20200147070A1 (en) Inducing phospholipidosis for enhancing therapeutic efficacy
TW202045206A (zh) 抗體調配物

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVO NORDISK A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PARSHAD, HENRIK;ENGELUND, DORTE KOT;SIGNING DATES FROM 20121128 TO 20121129;REEL/FRAME:029650/0215

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION